4//SEC Filing
GADICKE ANSBERT 4
Accession 0001231919-25-000533
CIK 0001785530other
Filed
Nov 19, 7:00 PM ET
Accepted
Nov 20, 5:50 PM ET
Size
23.1 KB
Accession
0001231919-25-000533
Insider Transaction Report
Form 4
MPM ONCOLOGY INNOVATIONS FUND LP
10% Owner
Transactions
- Sale
Common Stock
2025-11-20$0.89/sh−41,152$36,625→ 5,321,436 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-19$0.94/sh−66,324$62,345→ 5,362,588 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-18$0.93/sh−52,627$48,943→ 5,428,912 total(indirect: See Footnotes)
UBS Oncology Impact Fund L.P.
10% Owner
Transactions
- Sale
Common Stock
2025-11-19$0.94/sh−66,324$62,345→ 5,362,588 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-20$0.89/sh−41,152$36,625→ 5,321,436 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-18$0.93/sh−52,627$48,943→ 5,428,912 total(indirect: See Footnotes)
GADICKE ANSBERT
10% Owner
Transactions
- Sale
Common Stock
2025-11-19$0.94/sh−66,324$62,345→ 5,362,588 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-18$0.93/sh−52,627$48,943→ 5,428,912 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-20$0.89/sh−41,152$36,625→ 5,321,436 total(indirect: See Footnotes)
Transactions
- Sale
Common Stock
2025-11-19$0.94/sh−66,324$62,345→ 5,362,588 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-18$0.93/sh−52,627$48,943→ 5,428,912 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-20$0.89/sh−41,152$36,625→ 5,321,436 total(indirect: See Footnotes)
MPM BioImpact LLC
10% Owner
Transactions
- Sale
Common Stock
2025-11-19$0.94/sh−66,324$62,345→ 5,362,588 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-18$0.93/sh−52,627$48,943→ 5,428,912 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-20$0.89/sh−41,152$36,625→ 5,321,436 total(indirect: See Footnotes)
MPM Oncology Innovations Fund GP LLC
10% Owner
Transactions
- Sale
Common Stock
2025-11-20$0.89/sh−41,152$36,625→ 5,321,436 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-19$0.94/sh−66,324$62,345→ 5,362,588 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-18$0.93/sh−52,627$48,943→ 5,428,912 total(indirect: See Footnotes)
MPM ASSET MANAGEMENT LLC
10% Owner
Transactions
- Sale
Common Stock
2025-11-18$0.93/sh−52,627$48,943→ 5,428,912 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-20$0.89/sh−41,152$36,625→ 5,321,436 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-19$0.94/sh−66,324$62,345→ 5,362,588 total(indirect: See Footnotes)
Footnotes (11)
- [F1]Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
- [F10]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8506 to $0.9556 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F11]The shares are held as follows: 365,479 by AM LLC, 2,308,070 by BV 2014, 153,944 by BV 2014(B), 79,442 by AM BV2014, 506,192 by MPM OIF and 1,908,309 by UBS Oncology.
- [F2]The shares were sold as follows: 3,613 by MPM Asset Management LLC ("AM LLC"), 22,827 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,523 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 786 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 5,027 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 18,851 by UBS Oncology Impact Fund L.P. ("UBS Oncology").
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8902 to $0.9601 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
- [F5]The shares are held as follows: 372,858 by AM LLC, 2,354,688 by BV 2014, 157,054 by BV 2014(B), 81,046 by AM BV2014, 516,458 by MPM OIF and 1,946,808 by UBS Oncology.
- [F6]The shares were sold as follows: 4,554 by AM LLC, 28,768 by BV 2014, 1,919 by BV 2014(B), 990 by AM BV2014, 6,335 by MPM OIF and 23,758 by UBS Oncology.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.901 to $0.9806 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F8]The shares are held as follows: 368,304 by AM LLC, 2,325,920 by BV 2014, 155,135 by BV 2014(B), 80,056 by AM BV2014, 510,123 by MPM OIF and 1,923,050 by UBS Oncology.
- [F9]The shares were sold as follows: 2,825 by AM LLC, 17,850 by BV 2014, 1,191 by BV 2014(B), 614 by AM BV2014, 3,931 by MPM OIF and 14,741 by UBS Oncology.
Documents
Issuer
Werewolf Therapeutics, Inc.
CIK 0001785530
Entity typeother
Related Parties
1- filerCIK 0001134655
Filing Metadata
- Form type
- 4
- Filed
- Nov 19, 7:00 PM ET
- Accepted
- Nov 20, 5:50 PM ET
- Size
- 23.1 KB